💊 Oral, Potent, Proven — Enlicitide Redefines LDL Control
Dr RR Baliga's "Got Knowledge Doc" Podkast
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
🚀 A milestone moment in lipid therapeutics!
The new JAMA trial on the oral PCSK9 inhibitor Enlicitide reports a ~60% reduction in LDL-C, with parallel decreases in ApoB and Lp(a)—all on top of maximally tolerated statin therapy.
For individuals with heterozygous familial hypercholesterolemia (HeFH)—where reaching LDL targets remains a persistent challenge—this represents a major advance. An oral agent matching the potency of injectable PCSK9 inhibitors could reshape adherence, access, and long-term ASCVD prevention. 🌉💊
Safety was comparable to placebo, and effects were rapid, robust, and sustained to 52 weeks. The ongoing CORALreef Outcomes trial will determine its impact on major cardiovascular events. 🔬❤️
Innovation in lipid lowering is accelerating—and patient-centered options are expanding.
#JAMA #LipidManagement #HeFH #CardiovascularHealth #PCSK9 #Enlicitide #Prevention 🌟